Drugs for sleep disorders: Mechanisms and therapeutic prospects

British Journal of Clinical Pharmacology

Volumn 61, Issue 6, 2006, Pages 761-766

  Szabadi, Elemer ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Drug therapy; Neural mechanisms; Sleep disorders; Sleep promoting system; Wakefulness promoting systems

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMPHETAMINE DERIVATIVE; ANTIHISTAMINIC AGENT; GABOXADOL; GW 649868; HYPNOTIC SEDATIVE AGENT; INDIPLON; METHYLPHENIDATE; MODAFINIL; NG 273; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM; ZOPICLONE;

AROUSAL; BRAIN STEM; CATAPLEXY; DAYTIME SOMNOLENCE; DRUG MECHANISM; GABAERGIC SYSTEM; HUMAN; HYPERSOMNIA; HYPOTHALAMUS; INSOMNIA; LOCUS CERULEUS; MOOD DISORDER; NARCOLEPSY; NERVE CELL; NEUROTRANSMISSION; PARASOMNIA; PREOPTIC NUCLEUS; PRIORITY JOURNAL; RAPHE NUCLEUS; RESTLESSNESS; REVIEW; SLEEP; SLEEP DISORDER; VENTRAL TEGMENTUM;

ADENOSINE; AROUSAL; DOPAMINE AGENTS; HUMANS; HYPNOTICS AND SEDATIVES; MELATONIN; RECEPTORS, GABA; RECEPTORS, HISTAMINE; RECEPTORS, SEROTONIN; SLEEP DISORDERS; WAKEFULNESS;

EID: 33646924810     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02680.x     Document Type: Review

References (42)

1. Mitchell AJ. Neuropsychiatry and Behavioural Neurology Explained. Edinburgh: Saunders 2004.
2. Shneerson JM. Handbook of Sleep Medicine. Oxford: Blackwell Science 2000.
3. Kilduff TS, Peyron C. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci 2000 23: 359 65.
4. Sutcliffe JG, de Lecea L. The hypocretins: setting the arousal threshold. Nat Rev Neurosci 2002 3: 339 49.
5. US Modafinil in Narcolepsy Multicenter Study Group. Randomised trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998 43: 88 97.
6. Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, Barbanoj MJ. Differential effects of a new central adrenergic agonist - modafinil - and d-amphetamine on sleep and early morning behaviour in young healthy volunteers. Int J Clin Pharmacol Res 1989 9: 183 95.
7. Hou RH, Freeman C, Langley RW, Szabadi E, Bradshaw CM. Does modafinil activate the locus coeruleus in man? Comparison of modafinil and clonidine on arousal and autonomic functions in human volunteers. Psychopharmacology 2005 181: 537 49.
8. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002 72: 179 83.
9. Stankoff B, Waubant E, Confavreux C, Edan G, Debouverie M, Rumbach L, Moreau T, Pelletier J, Lubetzki C, Clanet M, French Modafinil Study Group. Modafinil for fatigue in MS: a randomised placebo-controlled double-blind study. Neurology 2005 64: 1139 43.
10. Saper CB, Scammell TE. Modafinil: a drug in search of a mechanism. Sleep 2004 27: 11 2.
11. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001 24: 726 31.
12. Pace-Schott EF, Hobson JA. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 2002 3: 591 605.
13. Mignot E, Taheri S, Nishino S. Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. Nat Neurosci 2002 5 Suppl. 1071 5.
14. Rudolph U. GABAergic system. In: Encyclopaedic Reference of Molecular Pharmacology, Offermanns S, Rosenthal W. Berlin: Springer 2004: 373 8.
15. Möhler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002 300: 2 8.
16. Pirker S, Schwarzer C, Wiesenthaler A, Sieghart W, Sperk G. GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 2000 101: 815 50.
17. Nelson LE, Guo TZ, Lu J, Saper CB, Franks NP, Maze M. The sedative component of anaesthesia is mediated by GABAA receptors in an endogenous sleep pathway. Nat Neurosci 2002 5: 979 84.
18. Domino EF. Sites of action of some central nervous depressants. Ann Rev Pharmacol 1962 2: 215 50.
19. Becker JR, Thomas S. Future Treatment for Depression, Anxiety, Sleep Disorders, Psychosis and ADHD. http://www.neurotransmitter.net/newdrugs.html 2006 (last accessed: 23 January 2006).
20. Gershell L. Insomnia market. Nat Rev Drug Discov 2006 5: 15 6.
21. Wafford KA, Ebert B. Gaboxadol - a new awakening in sleep. Curr Opinion Pharmacol 2006 6: 30 6.
22. Sorbera LA, Castaner J. Gaboxadol - treatment of sleep disorders; GABA(A) receptor agonist. Drugs Future 2004 29: 449 54.
23. Bernasconi R, Mathivet P, Bischoff S, Marescaux C. Gamma-hydroxybutyric acid: an endogenous neuromodulator with abuse potential? Trends Pharmacol Sci 1999 20: 135 41.
24. Sharf MB, Brown D, Woods M, Brown L, Hirschokitz J. The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. J Clin Psychiatry 1985 46: 222 5.
25. Scrima L, Hartman PG, Johnson FG, Thomas EE, Hiller FC. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double blind subjective measures. Biol Psychiatry 1989 26: 331 43.
26. Capai MA, Colombo G, Brunetti G, Melis S, Serra S, Vacca G, Mastinu S, Pistuddi AM, Solinas C, Cignarella G, Minardi G, Gessa GL. Role of GABA(B) receptors in the sedative/hypnotic effect of gamma-hydroxybutyric acid. Eur J Pharmacol 2001 428: 315 21.
27. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous sytem. Nat Rev Neurosci 2003 4: 121 30.
28. Tashiro M, Mochizuki H, Iwabuchi K, Sakurada Y, Itoh M, Watanabe T, Yanai K. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002 72: 409 14.
29. Passani MB, Lin J-S, Hancock A, Crochet S, Blandina P. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004 25: 618 25.
30. Ligneau X, Lin J-S, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, Schwartz J-C. Neurochemical and behavioural effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther 1998 287: 658 66.
31. Witkin JM, Nelson DL. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 2004 103: 1 20.
32. Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioural state and state-dependent cognitive processes. Brain Res Rev 2003 42: 33 84.
33. Nelson LE, Lu J, Guo T, Saper CB, Franks NP, Maze M. The α2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 2003 98: 428 36.
34. Rye DB. Parkinson's disease and RLS: the dopaminergic bridge. Sleep Med 2004 5: 317 28.
35. Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM. Comparison of pramipexole and modafinil on arousal, autonomic and endocrine functions in healthy volunteers. J Psychopharmacol 2006 in press.
36. Bubser M, Fadel JR, Jackson LL, Meador-Woodruff JH, Jing D, Deutch AY. Dopaminergic regulation of orexin neurons. Eur J Neurosci 2005 21: 2993 3001.
37. Trinkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol 2005 4: 465 75.
38. Abrams JK, Johnson PL, Hay-Schmidt A, Mikkelsen JD, Shekhar A, Lowry CA. Serotonergic systems associated with arousal and vigilance behaviours following administration of anxiogenic drugs. Neuroscience 2005 133: 983 97.
39. Graham SJ, Langley RW, Balboa Verduzco AM, Bradshaw CM, Szabadi E. Effects of ketanserin and haloperidol on prepulse inhibitions of the acoustic startle (eyeblink) response and the N1/P2 auditory evoked response in man. J Psychopharmacol 2002 16: 15 22.
40. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet J-M, Cussac D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003 306: 954 64.
41. Brzezinski A. Mechanisms of disease: melatonin in humans. N Engl J Med 1997 336: 186 95.
42. Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjørkum AA, Green RW, McCarley RW. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science 1997 276: 1265 8.